Medical technology company Clinical Laserthermia Systems (CSL) are active in image-guided laser ablation treatment of soft tissue, e.g. cancer tumors, with high precision. Laser ablation involves increasing the temperature in e.g. cancer cells by directing laser light into a tumor. This in turn leads to the destruction of the cancer cells. The treatment is guided by ultrasound or magnetic resonance imaging (MRI).
CLS both develops and sells products in the field of image-guided laser ablation. In addition to these products, the company is also evaluating a proprietary immunostimulatory treatment protocol, imIT, with the aim of being used in the treatment of advanced tumor disease in later stages.
TRANBERG Thermal Therapy System
CLS develops and sells TRANBERG Thermal Therapy Systems and MR thermometry equipment for image-guided laser ablation treatment with high precision. In the EU, CLS has chosen to initially focus on the treatment of prostate cancer, pancreatic cancer, brain tumors and epilepsy.
In the US, the TRANBERG system is used for the treatment of prostate cancer and arteriovenous malformations (AVMs). The system is also optimized for treatment with CLS' proprietary imILT protocol, which has the potential to stimulate the immune system.
Part of clinical study
Both the TRANBERG Thermal Therapy System and corresponding products from other suppliers have been used in a clinical study that evaluated treatment with MR image-guided percutaneous laser ablation and cryoablation, respectively. The non-randomized and retrospective study was conducted by, among others, dr. David Woodrum at American Mayo Clinic.
A total of 30 patients with painful vascular malformations of the trunk, arms/legs and hands were included. The patients were followed up for 6–12 months after treatment. Vascular malformations are one of the two indications that CLS has chosen to focus on with the TRANBERG Thermal Therapy System in the US market. The other is prostate cancer.
Promising results
The promising study results have been published in reputable Journal of Vascular and Interventional RadiologyFor 23 of the 30 included patients, there is complete follow-up, which shows, among other things, complete or partial reduction in pain and reduced swelling as an effect of the treatment.
It is also worth noting that although 9 patients experienced minor complications after treatment, none of them required advanced treatment. The scientific article emphasizes that MR thermometry is useful for guiding the ablation.
CLS acting CEO Dan Mogren commented on the study results and underlined its importance for the company in a press release:
»It is very pleasing that the study shows good results and that the TRANBERG products have worked as Dr. David Woodrum, and the rest of the group at the Mayo Clinic, desired for the treatment of vascular malformations. The conclusion of the study, which was conducted between 2014 and 2019, is that MR image-guided percutaneous laser ablation, as well as cryoablation, are safe and effective treatment methods for this type of painful condition, caused by malformed blood vessels, in the trunk and extremities. This study is an important reference for CLS in the market establishment of the TRANBERG system and I look forward to continued collaboration with Dr. Woodrum and his colleagues at the Mayo Clinic.«
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.
